德曲妥珠单抗对比医生选择方案治疗HER2阳性转移性乳腺癌(DESTINY-Breast02):随机、开放标签、多中心3期试验的患者报告结局
DESTINY-Breast02研究在227个中心纳入608例HER2阳性不可切除或转移性乳腺癌患者(既往接受过恩美曲妥珠单抗),按2:1随机接受德曲妥珠单抗或医生选择方案。患者报告结局显示两组总体健康状况维持稳定,德曲妥珠单抗组至明确恶化时间延迟(14.1个月 vs 5.9个月;HR 0.5573,p<0.0001),住院率相似但至住院时间更长。
要点
- 德曲妥珠单抗组EORTC QLQ-C30总体健康状况至明确恶化中位时间14.1个月,医生选择方案组5.9个月(HR 0.5573,p<0.0001)。
- 两组总体健康状况评分维持稳定,未出现≥10分的临床意义变化。
- 德曲妥珠单抗组住院率23%(92/406),医生选择方案组20%(41/202),至住院中位时间分别为133天和83天。
核心结论
- 两组总体健康状况和生活质量均得以维持,预设患者报告结局变量倾向于德曲妥珠单抗优于医生选择方案,提示尽管治疗持续时间更长,德曲妥珠单抗对患者健康相关生活质量无不利影响。
- 结合DESTINY-Breast02的疗效和安全性数据,这些结果支持德曲妥珠单抗对既往接受过恩美曲妥珠单抗治疗的HER2阳性不可切除或转移性乳腺癌患者的总体获益。
研究设计与样本
- 随机、开放标签、多中心3期试验,在全球227个临床中心开展。
- 纳入年龄≥18岁、HER2阳性不可切除或转移性乳腺癌、既往恩美曲妥珠单抗治疗进展、ECOG体能状态0或1的患者。
- 采用区组随机化(区组大小3)按2:1随机分配至德曲妥珠单抗组(406例)或医生选择方案组(202例)。
- 患者报告结局在全分析集(所有随机分配患者)中采用EORTC QLQ-C30、EORTC QLQ-BR45和EQ-5D-5L问卷评估。
主要发现
- 2018年9月6日至2020年12月31日共随机分配608例患者,德曲妥珠单抗组406例(2例未接受治疗),医生选择方案组202例(7例未接受治疗)。
- 德曲妥珠单抗组中位随访21.5个月(IQR 15.2-28.4),医生选择方案组18.6个月(IQR 8.8-26.0)。
- 德曲妥珠单抗组中位治疗持续时间11.3个月(IQR 6.2-20.5),医生选择方案组约4.5个月(曲妥珠单抗4.4个月[IQR 2.5-8.7]、卡培他滨4.6个月[2.1-8.9]、拉帕替尼4.5个月[2.1-10.6])。
- 主要患者报告结局变量EORTC QLQ-C30总体健康状况至明确恶化中位时间:德曲妥珠单抗组14.1个月(95%CI 10.4-18.7)vs 医生选择方案组5.9个月(95%CI 4.3-7.9);HR 0.5573(95%CI 0.4376-0.7099),p<0.0001。
- 所有其他预设患者报告结局(EORTC QLQ-C30子量表、EORTC QLQ-BR45手臂和乳房症状、EQ-5D-5L视觉模拟量表)均显示德曲妥珠单抗组至明确恶化时间延迟。
关键数值与推荐
- 德曲妥珠单抗给药方案:5.4 mg/kg静脉注射,每21天一次。
- 医生选择方案A:卡培他滨1250 mg/m2口服每日两次,第1-14天,联合曲妥珠单抗8 mg/kg静脉注射第1天后续6 mg/kg每日一次。
- 医生选择方案B:卡培他滨1000 mg/m2联合拉帕替尼1250 mg口服每日一次,第1-21天,21天为一周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. We present the patient-reported outcomes (PROs) and hospitalisation data. METHODS: In this randomised, open-label, phase 3 trial conducted at 227 clinical sites globally, enrolled patients had to be aged 18 years or older with HER2-positive unresectable or metastatic breast cancer that had progressed on trastuzumab emtansine and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (2:1) using block randomisation (block size of 3) to receive trastuzumab deruxtecan (5·4 mg/kg intravenously once every 21 days) or treatment of physician's choice by an independent biostatistician using an interactive web-based system. Patients and investigators remained unmasked to treatment. Treatment of physician's choice was either capecitabine (1250 mg/m2 orally twice per day on days 1-14) plus trastuzumab (8 mg/kg intravenously on day 1 then 6 mg/kg once per day) or capecitabine (1000 mg/m2) plus lapatinib (1250 mg orally once per day on days 1-21), with a 21-day schedule. The primary endpoint, which was progression-free survival based on blinded independent central review, has previously been reported. PROs were assessed in the full analysis set (all patients randomly assigned to the study) using the oncology-specific European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), breast cancer-specific EORTC Quality of Life Questionnaire Breast 45 (QLQ-BR45), and the generic HRQoL EQ-5D-5L questionnaire. Analyses included change from baseline and time to definitive deterioration for PRO variables of interest and hospitalisation-related endpoints. This study is registered with ClinicalTrials.gov, NCT03523585, and is closed to recruitment. FINDINGS: Between Sept 6, 2018, and Dec 31, 2020, 608 patients were randomly assigned to receive either trastuzumab deruxtecan (n=406; two did not receive treatment) or treatment of physician's choice (n=202; seven did not receive treatment). Overall, 603 patients (99%) were female and five (<1%) were male. The median follow-up was 21·5 months (IQR 15·2-28·4) in the trastuzumab deruxtecan group and 18·6 months (IQR 8·8-26·0) in the treatment of physician's choice group. Median treatment duration was 11·3 months (IQR 6·2-20·5) in the trastuzumab deruxtecan group and approximately 4·5 months in the treatment of physician's choice group (4·4 months [IQR 2·5-8·7] with trastuzumab; 4·6 months [2·1-8·9] with capecitabine; and 4·5 months [2·1-10·6] with lapatinib). Baseline EORTC QLQ-C30 global health status (GHS) scores were similar with trastuzumab deruxtecan (n=393) and treatment of physician's choice (n=187), and remained stable with no clinically meaningful change (defined as ≥10-point change from baseline) over time. Median time to definitive deterioration was delayed with trastuzumab deruxtecan compared with treatment of physician's choice for the primary PRO variable EORTC QLQ-C30 GHS (14·1 months [95% CI 10·4-18·7] vs 5·9 months [4·3-7·9]; HR 0·5573 [0·4376-0·7099], p<0·0001) and all other prespecified PROs (EORTC QLQ-C30 subscales, EORTC QLQ-BR45 arm and breast symptoms, and EQ-5D-5L visual analogue scale). Patient hospitalisation rates were similar in the trastuzumab deruxtecan (92 [23%] of 406) and treatment of physician's choice (41 [20%] of 202) groups; however, median time to hospitalisation was 133 days (IQR 56-237) with trastuzumab deruxtecan versus 83 days (30-152) with treatment of physician's choice. INTERPRETATION: Overall, GHS and quality of life were maintained for both treatment groups, with prespecified PRO variables favouring trastuzumab deruxtecan over treatment of physician's choice, suggesting that despite a longer treatment duration, there was no detrimental impact on patient health-related quality of life with trastuzumab deruxtecan. When considered with efficacy and safety data from DESTINY-Breast02, these results support the overall benefit of trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab emtansine. FUNDING: Daiichi Sankyo and AstraZeneca.
引用
- Fehm T, Cottone F, Dunton K, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024. PMID: 38697155. doi:10.1016/S1470-2045(24)00128-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。